Greater Bay Area International Clinical Trial Institute (GBAICTI) Biobank, Hong Kong

Certification Status: In Review

Registration Status: Completed

Objective: The establishment of the Greater Bay Area International Clinical Trial Institute (GBAICTI) at Lok Ma Chau Loop is pivotal in positioning Hong Kong as a prominent hub for health and medical innovation. This initiative will generate a significant demand for biobanking services that adhere to global standards, serving the varied research entities attracted from around the world. As part of the Health Bureau's directive, the Hospital Authority (HA) collaborates with the Chinese University of Hong Kong (CUHK) to establish a biobank at the GBAICTI. The GBAICTI Biobank aims to provide a diverse range of well-preserved human biological materials with detailed annotations to meet the research requirements of various groups in the region, thereby supporting medical research in the Greater Bay Area.

Registered Biobank Name	Greater Bay Area International Clinical Trial Institute (GBAICTI) Biobank
Biobank Leader	Dr. Terry Cho Tsun OR
Country	Hong Kong
Email for biobank inquiries	terryor@cuhk.edu.hk
Principal Investigator	Prof. Ronald Ching Wan MA, Prof. Ka Fai TO, Dr. Leo Ho Fung CHAN
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).